AIM-listed biotech firms face crunch votes on London Stock Exchange exits April 14, 2024 Redx Pharma and C4X Discovery have scheduled general meetings this week to vote on proposals for delisting from the London Stock Exchange.
Flush FTSE 100 giant Astrazeneca to give more back to shareholders with dividend hike April 11, 2024 AstraZeneca will increase its annual dividend for the year by $0.20 (16p) to $3.10 (£2.47) per share
Spring Budget 2024: £360m research package to boost British manufacturing March 4, 2024 The Spring Budget will include a £360m funding package to boost British manufacturing, research and development, including electric vehicles and pharmaceuticals.
GSK: Cancer claims plague pharma giant as it settles another Zantac case February 29, 2024 GSK has reached another confidential settlement in a Californian lawsuit that had alleged its best-selling indigestion drug, Zantac, was carcinogenic.
Astrazeneca share price rises as Tagrisso drug shows ‘highly impactful’ results in lung cancer trial February 19, 2024 Results from Tagrisso's Phase III trial showed a "statistically significant and highly clinically meaningful improvement" in progression-free survival.
Redx Pharma denies US listing plan following report February 14, 2024 Redx Pharma has denied it is currently in the process of listing in the US following a report in The Times.
GSK receives Fast Track designation for chronic hepatitis B drug in latest boost for pharma giant February 12, 2024 Pharmaceutical giant GSK has received a special recognition from the US Food and Drug Administration (FDA) for its bepirovirsen drug.
Pfizer/BioNTech Covid jab to be sold in UK high street pharmacies February 10, 2024 The Pfizer/BioNTech Covid jab will be sold in UK high street pharmacies from next month.
NHS pharmacy chain owed £40m before it was bought out of administration February 8, 2024 An estimated £40m was owed by NHS pharmacy chain Medipharmacy before it collapsed into administration and was rescued, it has been revealed.
GSK split seems to be paying off as vaccines drive upgraded profit guidance January 31, 2024 "We are now planning for at least 12 major launches from 2025, with new Vaccines and Specialty Medicines for infectious diseases, HIV, respiratory and oncology," Emma Walmsley, chief executive at GSK said.